ViroCell Biologics, a London, UK- and NYC-based cell and gene therapy contract development and manufacturing organization, raised an undisclosed amount in convertible note funding.
The round was led by First Light Asset Management LLC, joining existing investors including Sartorius Stedim Biotech S.A.
The company intends to use the funds to accelerate its growth, as it continues to gain commercial traction with its specialist services in viral vector design and manufacturing.
Led by CEO John W. Hadden II, ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization (“CDMO”) focused exclusively on the design, derisking, and GMP manufacture of viral vectors for clinical trials. The team leverages its track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators in this field. Focused initially on manufacturing lentivirus and gamma-retrovirus vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk.
FinSMEs
15/08/2024